BioMarin Pharmaceutical Inc (BMRN) Actualités

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

BioMarin to Participate in Three Upcoming Investor Conferences

BioMarin to Participate in Three Upcoming Investor Conferences PR Newswire SAN RAFAEL, Calif., Nov. 6, 2024...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance;...

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

WILMETTE, Ill., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage...

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related...

Form 4 - Statement of changes in beneficial ownership of securities